Metal drugs become targeted
Open Access
Abstract
Click here to see the linked paperKeywords
This publication has 17 references indexed in Scilit:
- Prospects for combining targeted and conventional cancer therapy with immunotherapyNature Reviews Cancer, 2017
- Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis ProgressionNeoplasia, 2016
- Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of actionJournal of Inorganic Biochemistry, 2016
- Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohortESMO Open, 2016
- Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapyInvestigational New Drugs, 2014
- The Molecular Chaperone GRP78/BiP in the Development of Chemoresistance: Mechanism and Possible TreatmentFrontiers in Pharmacology, 2013
- Anticancer Activity of Metal Complexes: Involvement of Redox ProcessesAntioxidants & Redox Signaling, 2011
- Arsenic Trioxide Controls the Fate of the PML-RARα Oncoprotein by Directly Binding PMLScience, 2010
- The resurgence of platinum-based cancer chemotherapyNature Reviews Cancer, 2007
- Intrinsic and Acquired Forms of Resistance against the Anticancer Ruthenium Compound KP1019 [Indazolium trans-[tetrachlorobis(1 H-indazole)ruthenate (III)] (FFC14A)The Journal of Pharmacology and Experimental Therapeutics, 2005